Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
August 1, 2024 3:59 PM EDTJefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
July 31, 2024 6:24 AM EDTRBC Capital analyst Daniel Busb lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "While PCRX continues to execute on delivering positive Exparel numbers through 1H, focus remains squarely on ongoing patent... More
